Nothing Special   »   [go: up one dir, main page]
create a website
The influence of cost-effectiveness and other factors on NICE decisions. (2013). Rice, Nigel ; Parkin, David ; Feng, Yan ; OaNeill, Phill ; Devlin, Nancy ; Dakin, Helen .
In: Working Papers.
RePEc:chy:respap:93cherp.

Full description at Econpapers || Download paper

Cited: 8

Citations received by this document

Cites: 37

References cited by this document

Cocites: 31

Documents which have cited the same bibliography

Coauthors: 0

Authors who have wrote about the same topic

Citations

Citations received by this document

  1. Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review. (2018). Lancsar, Emily ; Gu, Yuanyuan ; Ghijben, Peter ; Zavarsek, Silva.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:36:y:2018:i:3:d:10.1007_s40273-017-0586-1.

    Full description at Econpapers || Download paper

  2. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions. (2018). , Bernard ; Bernard, ; Wu, Olivia ; Ho, Carlos King.
    In: Applied Health Economics and Health Policy.
    RePEc:spr:aphecp:v:16:y:2018:i:1:d:10.1007_s40258-017-0339-5.

    Full description at Econpapers || Download paper

  3. Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR). (2017). Hoch, Jeffrey ; Sabharwal, Mona ; Beca, Jaclyn ; Masucci, Lisa.
    In: PharmacoEconomics - Open.
    RePEc:spr:pharmo:v:1:y:2017:i:4:d:10.1007_s41669-017-0018-3.

    Full description at Econpapers || Download paper

  4. Decision Making and Priority Setting: The Evolving Path Towards Universal Health Coverage. (2017). Fiorentini, Gianluca ; Fouda, Ayman ; Redekop, Ken ; Paolucci, Francesco.
    In: Applied Health Economics and Health Policy.
    RePEc:spr:aphecp:v:15:y:2017:i:6:d:10.1007_s40258-017-0349-3.

    Full description at Econpapers || Download paper

  5. Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation. (2015). Pertile, Paolo ; Forster, Martin ; Jobjornsson, Sebastian ; Burman, Carl-Fredrik .
    In: Discussion Papers.
    RePEc:yor:yorken:15/16.

    Full description at Econpapers || Download paper

  6. Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness. (2015). Svensson, Mikael ; Arnberg, Karl ; Nilsson, Fredrik.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:33:y:2015:i:11:p:1229-1236.

    Full description at Econpapers || Download paper

  7. NICE’s Cost-Effectiveness Range: Should it be Lowered?. (2014). Raftery, J..
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:32:y:2014:i:7:p:613-615.

    Full description at Econpapers || Download paper

  8. Common Drug Review Recommendations. (2012). Goeree, Ron ; Hopkins, Robert ; Miller, Elizabeth ; Rocchi, Angela .
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:30:y:2012:i:3:p:229-246.

    Full description at Econpapers || Download paper

References

References cited by this document

  1. Accessed 13th September 2013.
    Paper not yet in RePEc: Add citation now

  2. Appleby J, Devlin N, Parkin D, Buxton M, Chalkidou K. 2009. Searching for cost-effectiveness thresholds in the NHS. Soc Sci Med 91: 239-245.

  3. Baker R, Bateman I, Donaldson C, Jones-Lee M, Lancsar E, Loomes G, Mason H, Odejar M, Pinto Prades JL, Robinson A, Ryan M, Shackley P, Smith R, Sugden R, Wildman J; SVQ Research Team. 2010. Weighting and valuing quality adjusted life years: preliminary results from the social value of a QALY project. Health Technology Assessment 14:1-162.
    Paper not yet in RePEc: Add citation now

  4. Briggs A, Fenn P. 1998. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Economics 7:723-40.

  5. Carlin JB, Galati JC, Royston P. 2008. A new framework for managing and analyzing multiply imputed data in Stata. Stata Journal 8:49-67.

  6. Copas JB. 1983. Regression, prediction and shrinkage. J Royal Statist Soc B 45 : 311-354.
    Paper not yet in RePEc: Add citation now
  7. Culyer A, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, Sculpher, M, Brazier J. 2007. Searching for a threshold, not setting one: The role of the National Institute for Health and Clinical Excellence. Journal of Health Services Research and Policy 12: 56 - 58.
    Paper not yet in RePEc: Add citation now

  8. Culyer A. 2009. Deliberative Processes in Decisions about Health Care Technologies: Combining Different Types of Evidence, Values, Algorithms and People. OHE Briefing no 48. London: Office of Health Economics.

  9. Culyer AJ. 2006 NICE's use of cost-effectiveness as an exemplar of a deliberative process. Health Economics, Policy and Law 1: 299-318.

  10. Culyer, AJ, Lomas, J, 2006. Deliberative processes and evidence-informed decision-making in health care – do they work and how might we know? Evidence and Policy 2: 357- 371.
    Paper not yet in RePEc: Add citation now
  11. Curtis L. 2012. Unit Costs of Health and Social Care 2012. Canterbury, UK: PSSRU Personal Social Services Research Unit. Available at: www.pssru.ac.uk/project-pages/unit-costs/2012/. Accessed 30th July 2013.
    Paper not yet in RePEc: Add citation now

  12. Dakin HA, Devlin NJ, Odeyemi IA. 2006. Yes, No or Yes, but? Multinomial modelling of NICE decision-making. Health Policy 77:352-67.

  13. Devlin N , Sussex J. 2011. Incorporating Multiple Criteria in HTA: Methods and Processes. London: Office of Health Economics.

  14. Devlin N,Parkin D. 2004. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 13:437-52.

  15. Hirth RA, Chernew ME, Miller E, Fendrick M, Weissert WG.2000. Willingness to pay for a qualityadjusted life year. Med Decis Making 20:332-42.
    Paper not yet in RePEc: Add citation now

  16. Linley WG,Hughes DA. 2012. Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors. Pharmacoeconomics 30:779-94.

  17. Littlejohns P, Rawlins M. 2009. Social value judgements: implementing the citizen’s council reports. Chapter 12 in: Littlejohns P, Rawlins M (eds) Patients, the Public and Priorities in Health Care. Radcliffe.
    Paper not yet in RePEc: Add citation now
  18. Mason AR, Drummond MF.2009. Public funding of new cancer drugs: Is NICE getting nastier? European Journal of Cancer 45:1188-92.
    Paper not yet in RePEc: Add citation now

  19. Mason H, Jones-Less A, Donaldson C. 2009. Modelling the monetary value of a QALY: a new approach based on UK data. Health Economics 18: 933-50.

  20. McCabe M, Claxton K, Culyer AJ.2008. The NICE cost-effectiveness threshold. What it is and what that means. Pharmacoeconomics 26:733-44.

  21. Methods for the estimation of the NICE cost effectiveness threshold. CHE Research Paper 81 http://www.york.ac.uk/media/che/documents/papers/researchpapers/CHERP81_methods_estimati on_NICE_costeffectiveness_threshold_revised.pdf Accessed 8th November 2013.
    Paper not yet in RePEc: Add citation now
  22. Mshelia I, White R, Mukke S, 2013. An investigation into the key drivers influencing the decision making of the Scottish Medicines Consortium. Value in Health 2013 16: A264 National Institute for Health and Clinical Excellence. 2010. NICE says “yes” to over 80% of treatments. Available at: www.nice.org.uk/newsroom/news/NICEsaysYes.jsp?domedia=1&mid=E99E7EDB-19B9-E0B5D4FCD1EB8398B6DD.
    Paper not yet in RePEc: Add citation now
  23. National Institute for Health and Clinical Excellence. 2004. Guide to the methods of technology appraisal. Available at: http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf. Accessed 18th November 2010.
    Paper not yet in RePEc: Add citation now
  24. National Institute for Health and Clinical Excellence. 2005. Social value judgements: Principles for the development of NICE guidance. Available at: http://www.nice.org.uk.
    Paper not yet in RePEc: Add citation now
  25. National Institute for Health and Clinical Excellence. 2008. Social value judgements: Principles for the development of NICE guidance. Second Edition. Available at: http://www.nice.org.uk/media/C18/30/SVJ2PUBLICATION2008.pdf. Accessed 13th November 2010.
    Paper not yet in RePEc: Add citation now
  26. National Institute for Health and Clinical Excellence. 2009. Appraising life extending, end of life treatments. Supplementary advice to the Appraisal Committees. Available at: www.nice.org.uk/aboutnice/howwework/devnicetech/endoflifetreatments.jsp?domedia=1&mid=88 ACDAE5-19B9-E0B5-D422589714A8EC6D. Accessed 13th September 2013.
    Paper not yet in RePEc: Add citation now
  27. National Institute for Health and Clinical Excellence. 2013. Guide to the methods of technology appraisal. Available at: http://www.nice.org.uk/media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdf. Accessed 3rd October 2013.
    Paper not yet in RePEc: Add citation now
  28. Rawlins M, Barnett D, Stevens A. 2010. Pharmacoeconomics: NICE’s approach to decision making. British Journal of Clinical Pharmacology 70: 346-349.
    Paper not yet in RePEc: Add citation now
  29. Rawlins M, Culyer A J. 2004. National Institute for Clinical Excellence and its value judgements. British Medical Journal 329: 224-227.
    Paper not yet in RePEc: Add citation now

  30. Rosen S. 1974. Hedonic prices and implicit markets: product differentiation in pure competition. The Journal of Political Economy 82, 34-55.

  31. Stafinski T, Menon D, Davis C, McCabe C. 2011. Role of centralized review processes for making reimbursement decisions on new health technologies in Europe. ClinicoEconomics and Outcomes Research 3: 117–186.
    Paper not yet in RePEc: Add citation now
  32. StataCorp. 2011. Stata: Release 12. Statistical Software (http://www.stata.com). College Station, TX: StataCorp LP.
    Paper not yet in RePEc: Add citation now
  33. Tappenden P, Brazier J, Ratcliffe J, Chilcott J. 2007 A stated preference binary choice experiment to explore NICE decision making. Pharmacoeconomics 25:685-93.
    Paper not yet in RePEc: Add citation now

  34. The influence of cost-effectiveness and other factors on NICE decisions 19 Harris AH, Hill SR, Chin G, Li JJ, Walkom E. 2008. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Med Decis Making 28:713–722.

  35. White I R, Royston P, Wood, A.M. 2011. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 30: 377-399.
    Paper not yet in RePEc: Add citation now
  36. WHO, World Health Organisation. 2004. Global Burden of Disease 2004 Update: Disability Weights For Diseases and Conditions. Available at: http://www.who.int/healthinfo/global_burden_disease/GBD2004_DisabilityWeights.pdf. Accessed 26th July 2013.
    Paper not yet in RePEc: Add citation now
  37. Williams I, Bryan S, McIver S. 2007. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach. J Health Serv Res Policy 12: 73-9. The influence of cost-effectiveness and other factors on NICE decisions 21
    Paper not yet in RePEc: Add citation now

Cocites

Documents in RePEc which have cited the same bibliography

  1. Competition, value-based prices and incentives to research personalised drugs. (2024). Levaggi, Rosella.
    In: Socio-Economic Planning Sciences.
    RePEc:eee:soceps:v:93:y:2024:i:c:s0038012124000697.

    Full description at Econpapers || Download paper

  2. The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS. (2022). Asaria, Miqdad ; Baal, Pieter ; Lomas, James ; Perry-Duxbury, Megan.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:40:y:2022:i:2:d:10.1007_s40273-021-01090-x.

    Full description at Econpapers || Download paper

  3. Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy. (2022). Hughes, Dyfrig A ; Garcia-Lorenzo, Borja ; Devlin, Nancy ; Cubi-Molla, Patricia ; Chalkidou, Kalipso ; Cairns, John ; Watson, Sam ; Zamora, Bernarda ; Sampson, Chris ; Towse, Adrian ; Leech, Ashley A.
    In: Applied Health Economics and Health Policy.
    RePEc:spr:aphecp:v:20:y:2022:i:5:d:10.1007_s40258-022-00730-3.

    Full description at Econpapers || Download paper

  4. Strategies for Avoiding Neglect of Opportunity Costs by Decision-Makers. (2022). Afzali, Hossein ; Partington, Andrew ; Karnon, Jonathan.
    In: Applied Health Economics and Health Policy.
    RePEc:spr:aphecp:v:20:y:2022:i:1:d:10.1007_s40258-021-00681-1.

    Full description at Econpapers || Download paper

  5. Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment. (2022). Faria, Rita ; Ochalek, Jessica ; Lomas, James.
    In: Applied Health Economics and Health Policy.
    RePEc:spr:aphecp:v:20:y:2022:i:1:d:10.1007_s40258-021-00679-9.

    Full description at Econpapers || Download paper

  6. The health cost of reducing hospital bed capacity. (2022). Henriksson, Martin ; Siverskog, Jonathan.
    In: Social Science & Medicine.
    RePEc:eee:socmed:v:313:y:2022:i:c:s0277953622007055.

    Full description at Econpapers || Download paper

  7. NICE’s Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests. (2021). McCabe, Chris ; Paulden, Mike ; Omahony, James F.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:39:y:2021:i:2:d:10.1007_s40273-020-00990-8.

    Full description at Econpapers || Download paper

  8. The relevance of including future healthcare costs in cost-effectiveness threshold calculations for the UK NHS. (2021). Perry-Duxbury, Megan ; van Baal, Pieter ; Asaria, Miqdad ; Lomas, James.
    In: LSE Research Online Documents on Economics.
    RePEc:ehl:lserod:112503.

    Full description at Econpapers || Download paper

  9. .

    Full description at Econpapers || Download paper

  10. .

    Full description at Econpapers || Download paper

  11. .

    Full description at Econpapers || Download paper

  12. Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL). (2018). Hampson, Grace ; Garau, Martina ; Devlin, Nancy ; Profico, Antonio ; Mazzanti, Nicola Amedeo.
    In: PharmacoEconomics - Open.
    RePEc:spr:pharmo:v:2:y:2018:i:2:d:10.1007_s41669-017-0048-x.

    Full description at Econpapers || Download paper

  13. Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System. (2018). Cheng, Terence ; Ali, Hossein Haji ; Edney, Laura Catherine ; Karnon, Jonathan.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:36:y:2018:i:2:d:10.1007_s40273-017-0585-2.

    Full description at Econpapers || Download paper

  14. Rationing in health care provision: a welfare approach. (2017). LEVAGGI, ROSELLA.
    In: International Journal of Health Economics and Management.
    RePEc:kap:ijhcfe:v:17:y:2017:i:2:d:10.1007_s10754-016-9209-1.

    Full description at Econpapers || Download paper

  15. Sustainable Financing of Innovative Therapies: A Review of Approaches. (2016). Hollis, Aidan.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:34:y:2016:i:10:d:10.1007_s40273-016-0416-x.

    Full description at Econpapers || Download paper

  16. Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma. (2016). , Manon ; Peppelenbosch, Maikel P ; Lordick, Florian ; Lorenzen, Sylvie ; Polinder, Suzanne ; Bruno, Marco J ; Janmaat, Vincent T.
    In: PLOS ONE.
    RePEc:plo:pone00:0153943.

    Full description at Econpapers || Download paper

  17. Welfare analysis of rationing in health care provision. (2016). LEVAGGI, ROSELLA.
    In: Working papers.
    RePEc:ipu:wpaper:39.

    Full description at Econpapers || Download paper

  18. Supporting the development of an essential health package: principles and initial assessment for Malawi. (2016). Sculpher, Mark ; Revill, Paul ; Claxton, Karl ; Ochalek, Jessica ; Rollinger, Alexandra .
    In: Working Papers.
    RePEc:chy:respap:136cherp.

    Full description at Econpapers || Download paper

  19. The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions. (2015). Rice, Nigel ; Parkin, David ; O'Neill, Phill ; Feng, Yan ; Devlin, Nancy ; Dakin, Helen .
    In: Health Economics.
    RePEc:wly:hlthec:v:24:y:2015:i:10:p:1256-1271.

    Full description at Econpapers || Download paper

  20. Local health care expenditure plans and their opportunity costs. (2015). Karlsberg, Sarah ; Walker, Andrew ; Devlin, Nancy ; Sussex, Jon ; Schaffer, Sarah Karlsberg .
    In: Health Policy.
    RePEc:eee:hepoli:v:119:y:2015:i:9:p:1237-1244.

    Full description at Econpapers || Download paper

  21. Pricing schemes for new drugs: A welfare analysis. (2014). LEVAGGI, ROSELLA.
    In: Social Science & Medicine.
    RePEc:eee:socmed:v:102:y:2014:i:c:p:69-73.

    Full description at Econpapers || Download paper

  22. Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall. (2013). van Exel, Job ; Brouwer, Werner ; Wetering, E. ; Stolk, E..
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:14:y:2013:i:1:p:107-115.

    Full description at Econpapers || Download paper

  23. Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold. (2013). Towse, Adrian ; Karlsberg, Sarah ; Karlsberg Schaffer, Sarah ; Sussex, J ; Barnsley, P.
    In: Occasional Papers.
    RePEc:ohe:occpap:000106.

    Full description at Econpapers || Download paper

  24. The influence of cost-effectiveness and other factors on NICE decisions. (2013). Rice, Nigel ; Parkin, David ; Feng, Yan ; OaNeill, Phill ; Devlin, Nancy ; Dakin, Helen .
    In: Working Papers.
    RePEc:chy:respap:93cherp.

    Full description at Econpapers || Download paper

  25. Comparing costs and outcomes across programmes of health care. (2012). Rice, Nigel ; Martin, Stephen ; Smith, Peter C..
    In: Health Economics.
    RePEc:wly:hlthec:v:21:y:2012:i:3:p:316-337.

    Full description at Econpapers || Download paper

  26. The Cost Effectiveness of Newer Epilepsy Treatments. (2012). Forsgren, Lars ; Bolin, Kristian.
    In: PharmacoEconomics.
    RePEc:spr:pharme:v:30:y:2012:i:10:p:903-923.

    Full description at Econpapers || Download paper

  27. The monetary value of a life year: evidence from a qualitative study of treatment costs. (2011). Richardson, Jeff ; Hurworth, Rosalind ; McKie, John ; Shrimpton, Bradley .
    In: Health Economics.
    RePEc:wly:hlthec:v:20:y:2011:i:8:p:945-957.

    Full description at Econpapers || Download paper

  28. Welfare properties of restrictions to health care based on cost effectiveness. (2011). LEVAGGI, ROSELLA.
    In: Health Economics.
    RePEc:wly:hlthec:v:20:y:2011:i:1:p:101-110.

    Full description at Econpapers || Download paper

  29. Shifting the risk in pricing and reimbursement schemes? A model of risk-sharing agreements for innovative drugs. (2011). LEVAGGI, ROSELLA ; Capri, Stefano .
    In: DEP - series of economic working papers.
    RePEc:gea:wpaper:2/2011.

    Full description at Econpapers || Download paper

  30. Appropriate Perspectives for Health Care Decisions. (2010). Walker, Simon ; Sculpher, Mark ; Claxton, Karl ; Palmer, Steven .
    In: Working Papers.
    RePEc:chy:respap:54cherp.

    Full description at Econpapers || Download paper

  31. Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?. (2009). Johannesson, Magnus ; Zethraeus, N ; Kobelt, G ; Jonsson, L.
    In: Briefings.
    RePEc:ohe:briefg:000228.

    Full description at Econpapers || Download paper

Coauthors

Authors registered in RePEc who have wrote about the same topic

Report date: 2025-01-17 09:22:14 || Missing content? Let us know

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated October, 6 2023. Contact: CitEc Team.